Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.48 |
| ▸ | GSK3A | P49840 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3151005 | 1.00 | GSK3B (0.50) | GSK3BMAPTKDM4CGSK3AALDH1A1 | |
| D-Alanine SCHEMBL17373191 | 0.88 | AKR1C3 (0.43) | GSK3BMAPTKDM4CGSK3AALDH1A1 | |
| Alanine SCHEMBL17373190 | 0.88 | AKR1C3 (0.43) | GSK3BMAPTKDM4CGSK3AALDH1A1 | |
| SCHEMBL3159846 | 0.87 | RPS6KA3 (0.46) | GSK3BMAPTKDM4CGSK3ACYP3A4 | |
| SCHEMBL2001092 | 0.85 | GSK3B (0.40) | GSK3BMAPTKDM4CGSK3APIP4K2A | |
| SCHEMBL2003108 | 0.85 | KDM4C (0.45) | KDM4CPIP4K2A | |
| SCHEMBL1999410 | 0.84 | SLC22A12 (0.49) | GSK3BMAPTGSK3ASLC22A12 | |
| SCHEMBL3156833 | 0.84 | SLC22A12 (0.52) | GSK3BGSK3ASLC22A12CYP3A4CYP2C9 | |
| SCHEMBL3150902 | 0.83 | LIMK1 (0.48) | GSK3BKDM4CGSK3APIP4K2A | |
| SCHEMBL2000076 | 0.83 | GSK3B (0.44) | GSK3BMAPTKDM4CGSK3APIP4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254186-A1 | GLP-1 Receptor Agonists Having Improved Pharmacological and Drug Delivery Properties | DARBIX LLC | 2024-08-01 | — | — | US | claimed |
| EP-4355348-A2 | GLP-1 RECEPTOR AGONISTS HAVING IMPROVED PHARMACOLOGICAL AND DRUG DELIVERY PROPERTIES | Darbix LLC (US) | 2024-04-24 | — | — | EP | claimed |
| US-20230015478-A1 | GLP-1 RECEPTOR AGONISTS HAVING IMPROVED PHARMACOLOGICAL AND DRUG DELIVERY PROPERTIES | RESOLUTE BIO INC (US) | 2023-01-19 | — | — | US | claimed |
| WO-2022266068-A2 | GLP-1 RECEPTOR AGONISTS HAVING IMPROVED PHARMACOLOGICAL AND DRUG DELIVERY PROPERTIES | RESOLUTE BIO, INC. (US) | 2022-12-22 | — | — | WO | claimed |
| EP-1773877-B1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | claimed |
| US-20060287242-A1 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | claimed |
| US-20240254186-A1 | GLP-1 Receptor Agonists Having Improved Pharmacological and Drug Delivery Properties | DARBIX LLC | 2024-08-01 | — | — | US | disclosed |
| EP-4355348-A2 | GLP-1 RECEPTOR AGONISTS HAVING IMPROVED PHARMACOLOGICAL AND DRUG DELIVERY PROPERTIES | Darbix LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20230015478-A1 | GLP-1 RECEPTOR AGONISTS HAVING IMPROVED PHARMACOLOGICAL AND DRUG DELIVERY PROPERTIES | RESOLUTE BIO INC (US) | 2023-01-19 | — | — | US | disclosed |
| WO-2022266068-A2 | GLP-1 RECEPTOR AGONISTS HAVING IMPROVED PHARMACOLOGICAL AND DRUG DELIVERY PROPERTIES | RESOLUTE BIO, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| EP-1773877-B1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2008-10-02 | — | — | US | disclosed |
| US-7417028-B2 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1773877-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060287242-A1 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
| WO-2006014287-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230015478-A1 | GLP-1 RECEPTOR AGONISTS HAVING IMPROVED PHARMACOLOGICAL AND DRUG DELIVERY PROPERTIES | GLP1R, GIPR, IAPP | GSK3B 2043/4885MAPT 3170/4885KDM4C 4748/4885 |
| US-20060287242-A1 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | GLP1R, GIPR, IAPP | GSK3B 2372/4885MAPT 4763/4885KDM4C 3162/4885 |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, GIPR, IAPP | GSK3B 2406/4885MAPT 4689/4885KDM4C 3492/4885 |
| US-20240254186-A1 | GLP-1 Receptor Agonists Having Improved Pharmacological and Drug Delivery Properties | GLP1R, GIPR, IAPP | GSK3B 2043/4885MAPT 3170/4885KDM4C 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.